Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy

Pathology Research and Practice

Volumn 206, Issue 9, 2010, Pages 607-610

  Soyuer, Serdar ^a   Soyuer, Isin ^a   Unal, Dilek ^a   Ucar, Kadir ^b   Yildiz, Oguz Galip ^a   Orhan, Okan ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b Acibadem Hospital   (Turkey)

Author keywords

CD9 expression; Gastric cancer; Prognosis

Indexed keywords

CD9 ANTIGEN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD; CHEMOTHERAPY, ADJUVANT; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77956011418     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.04.004     Document Type: Article

References (35)

1. Anton E.S., Hadjiargyrou M., Patterson P.H., Matthew W.D. CD9 plays a role in Schwann cell migration in vitro. J. Neurosci. 1995, 15:584-595.
2. Boucheix C., Rubinstein E. Tetraspanins. Cell. Mol. Life Sci. 2001, 58:1189-1205.
3. Erovic B.M., Pammer J., Hollemann D., Woegerbauer M., Geleff S., Fischer M.B., Burian M., Frommlet F., Neuchrist C. Motility-related protein-1/CD9 expression in head and neck squamous cell carcinoma. Head Neck 2003, 25:848-857.
4. Hadjiargyrou M., Patterson P.H. An anti-CD9 monoclonal antibody promotes adhesion and induces proliferation of Schwann cells in vitro. J. Neurosci. 1995, 15:574-583.
5. Hemler M.E., Mannion B.A., Berditchevski F. Association of TM4SF proteins with integrins: relevance to cancer. Biochim. Biophys. Acta 1996, 1297:67-71.
6. Higashiyama M., Doi O., Kodama K., Yokouchi H., Adachi M., Huang C.L., Taki T., Kasugai T., Ishiguro S., Nakamori S., Miyake M. Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int. J. Cancer 1997, 74:205-211.
7. Higashiyama M., Taki T., Ieki Y., Adachi M., Huang C.L., Koh T., Kodama K., Doi O., Miyake M. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res. 1995, 55:6040-6044.
8. Higashiyama S., Iwamoto R., Goishi K., Raab G., Taniguchi N., Klagsbrun M., Mekada E. The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J. Cell. Biol. 1995, 128:929-938.
9. Hori H., Yano S., Koufuji K., Takeda J., Shirouzu K. CD9 expression in gastric cancer and its significance. J. Surg. Res. 2004, 117:208-215.
10. Huang C.I., Kohno N., Ogawa E., Adachi M., Taki T., Miyake M. Correlation of reduction in MRP-1/CD9 and KA1/CD82 expression with recurrences in breast cancer patients. Am. J. Pathol. 1998, 153:973-983.
11. Kubista B., Erovic B.M., Klinger H., Sulzbacher I., Trieb K. CD9 expression is not a prognostic factor in human osteosarcoma. Cancer Lett. 2004, 209:105-110.
12. Kusukawa J., Ryu F., Kameyama T., Mekada E. Reduced expression of CD9 in oral squamous cell carcinoma: CD9 expression inversely related to high prevalence of lymph node metastasis. J. Oral. Pathol. Med. 2001, 30:73-79.
13. Maecker H.T., Todd S.C., Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J. 1997, 11:428-442.
14. Masellis Smith A., Shaw A.R. CD9-regulated adhesion. Anti-CD9 monoclonal antibody induces pre-B cell adhesion to bone marrow fibroblasts through de novo recognition of fibronectin. J. Immunol. 1994, 152:2768-2777.
15. Mhawech P., Dulguerov P., Tschanz E., Verdan C., Ares C., Allal A.S. Motility-related protein-1 (MRP-1/CD9) expression can predict disease-free survival in patients with squamous cell carcinoma of the head and neck. Br. J. Cancer 2004, 90:471-475.
16. Miyake M., Koyoma M., Seno M., Ikeyama S. Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J. Exp. Med. 1991, 174:1347-1354.
17. Miyake M., Nakano K., Ieki Y., Adachi M., Huang C.L., Itoi S., Koh T., Taki T. Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer. Cancer Res. 1995, 55:4127-4131.
18. Miyake M., Nakano K., Itoi S.I., Koh T., Taki T. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res. 1996, 56:1244-1249.
19. Miyamoto S., Maruyama A., Okugawa K., Akazawa K., Baba H., Maehara Y., Mekada E. Loss of motility-related protein 1 (MRP1/CD9) and integrin alpha3 expression in endometrial cancers. Cancer 2001, 92:542-548.
20. Mori M., Mimori K., Shiraishi T., Haraguchi M., Ueo H., Barnard G.F., Akiyoshi T. Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin. Cancer Res. 1998, 4:1507-1510.
21. Murayama Y., Miyagawa J., Shinomura Y., Kanayama S., Isozaki K., Yamamori K., Mizuno H., Ishiguro S., Kiyohara T., Miyazaki Y., Taniguchi N., Higashiyama S., Matsuzawa Y. Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int. J. Cancer 2002, 98:505-513.
22. Murayama Y., Shinomura Y., Oritani K., Miyagawa J., Yoshida H., Nishida M., Katsube F., Shiraga M., Miyazaki T., Nakamoto T., Tsutsui S., Tamura S., Higashiyama S., Shimomura I., Hayashi N. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. J. Cell. Physiol. 2008, 216:135-143.
23. Naef M., Yokoyama M., Friess H., Büchler M.W., Korc M. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int. J. Cancer 1996, 66:315-321.
24. Nakamoto T., Murayama Y., Oritani K., Boucheix C., Rubinstein E., Nishida M., Katsube F., Watabe K., Kiso S., Tsutsui S., Tamura S., Shinomura Y., Hayashi N. A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J. Gastroenterol. 2009, 44:889-896.
25. Nakazawa Y., Sato S., Naito M., Kato Y., Mishima K., Arai H., Tsuruo T., Fujita N. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood 2008, 112:1730-1739.
26. Ovalle S., Gutiérrez-López M.D., Olmo N., Turnay J., Lizarbe M.A., Majano P., Molina-Jiménez F., López-Cabrera M., Yáñez-Mó M., Sánchez-Madrid F., Cabañas C. The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. Int. J. Cancer 2007, 121:2140-2152.
27. Satoh M., Ito A., Nojiri H., Handa K., Numahata K., Ohyama C., Saito S., Hoshi S., Hakomori S.I. Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells. Int. J. Urol. 2001, 19:723-731.
28. Sauer G., Kurzeder C., Grundmann R., Kreienberg R., Zeillinger R., Deissler H. Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. Oncol. Rep. 2003, 10:405-410.
29. Schmidt C., Kunemund V., Wintergerst E.S., Schmitz B., Schachner M. CD9 of mouse brain is implicated in neurite outgrowth and cell migration in vitro and is associated with the alpha 6/beta 1 integrin and the neural adhesion molecule L1. J. Neurosci. Res. 1996, 43:12-31.
30. Shaw A.R., Domanska A., Mak A., Gilchrist A., Dobler K., Visser L., Poppema S., Fliegel L., Letarte M., Willett B.J. Ectopic expression of human and feline CD9 in a human B cell line confers beta 1 integrin-dependent motility on fibronectin and laminin substrates and enhanced tyrosine phosphorylation. J. Biol. Chem. 1995, 270:24092-24099.
31. Sho M., Adachi M., Taki T., Hashida H., Konishi T., Huang C.L., Ikeda N., Nakajima Y., Kanehiro H., Hisanaga M., Nakano H., Miyake M. Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int. J. Cancer 1998, 79:509-516.
32. Si Z., Hersey P. Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma. Int. J. Cancer 1993, 54:37-43.
33. Uchida S., Shimada Y., Watanabe G., Li Z.G., Hong T., Miyake M., Imamura M. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in esophageal squamous cell carcinoma. Br. J. Cancer 1999, 79:1168-1173.
34. Wright M.D., Tomlinson M.G. The ins and outs of the transmembrane 4 superfamily. Immunol. Today 1994, 15:588-594.
35. Yau J.C., Dabbagh L.K., Formenti K.S., Coupland R.W., Burns B.F., Shaw A.R. Expression of transmembrane 4 superfamily member, CD9, is related to improved progression-free survival in patients with diffuse non-Hodgkin's lymphoma. Oncol. Rep. 1998, 5:1507-1511.